Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of semaglutide injection versus Wegovy for weight loss in adults with obesity
ChiCTR2500100289Phase 3Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Body weight change at week 44. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2500100289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100289.